ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
ESMO 2022: Combination of cabozantinib, nivolumab and ipilimumab for patients with advanced kidney cancer with high-risk disease
The results of COSMIC-131 were presented at the European Society [...]
Neutrophil-eosinophil ratio predicts response of kidney cancer to ipilimumab plus nivolumab
Neutrophils and eosinophils are white blood cells. In this study, [...]
Nivolumab plus ipilimumab for localised kidney cancer
In a recent phase 3 clinical trial the combination of [...]
Adjuvant nivolumab plus ipilimumab for kidney cancer
Adjuvant therapy is medication that is given after surgery to [...]
Nivolumab compared to cabozantinib as a second- or third-line treatment
This study looked at real world data from people with [...]
Cabozantinib plus nivolumab and ipilimumab delays progression in kidney cancer
Preliminary results from the COSMIC-313 clinical trial have ben released. [...]
Statins improve the effectiveness of nivolumab for advanced kidney cancer
Statins are a group of medicines that can help lower [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
